Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

New findings demonstrating pharmacoeconomic benefits of Ceplene released

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Seattle Genetics reports its third-quarter financial results

Seattle Genetics reports its third-quarter financial results

Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

MDS secures international cooperation to help Canadian teenager with malignant blood disorder

MDS secures international cooperation to help Canadian teenager with malignant blood disorder

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

FDA provides Genzyme a complete response letter for Clolar NDA

FDA provides Genzyme a complete response letter for Clolar NDA

Researchers find new ways to treat Myelodysplastic Syndrome

Researchers find new ways to treat Myelodysplastic Syndrome

EPO and growth factor therapy safe for anemic MDS patients

EPO and growth factor therapy safe for anemic MDS patients

New peptide-based cancer vaccine tested in genital cancer patients

New peptide-based cancer vaccine tested in genital cancer patients

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Two 2008 drug approval reports highlight Ceplene benefits

Two 2008 drug approval reports highlight Ceplene benefits

ODAC calls for randomized study of Vion's Onrigin injection for treatment of the elderly AML patients

ODAC calls for randomized study of Vion's Onrigin injection for treatment of the elderly AML patients

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Combined therapy for acute leukemia shows promising results

Combined therapy for acute leukemia shows promising results

Researchers develop new ways for splitting dangerous pair of cancer proteins

Researchers develop new ways for splitting dangerous pair of cancer proteins

Vion Pharmaceuticals announces ODAC meeting for lead oncology therapeutic Onrigin

Vion Pharmaceuticals announces ODAC meeting for lead oncology therapeutic Onrigin

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.